Adagene Inc. SEC filings ADAG

Adagene Inc. has 191 filings in SEC EDGAR's recent list, going back to Sep 22, 2020. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 25, 2026. The company's fiscal year ends on December 31.

Adagene Inc. SEC filings
Form Description Filed Period
424B5 Prospectus supplement Apr 2, 2026 —
424B5 Prospectus supplement Apr 2, 2026 —
424B3 Prospectus Jan 9, 2026 —
F-3 Shelf registration (foreign issuer) Oct 31, 2025 —
424B5 Prospectus supplement May 30, 2025 —
F-3/A Filing May 23, 2025 —
F-3 Shelf registration (foreign issuer) May 9, 2025 —
424B5 Prospectus supplement Mar 29, 2024 —
F-3/A Filing May 20, 2022 —
F-3/A Filing May 13, 2022 —
F-3 Shelf registration (foreign issuer) Apr 26, 2022 —
S-8 Employee stock plan registration Apr 15, 2021 —
424B4 Prospectus Feb 10, 2021 —
F-1/A Filing Feb 5, 2021 —
F-1/A Filing Feb 3, 2021 —
F-1/A Filing Feb 1, 2021 —
F-6 Registration statement for american depositary receipts Jan 29, 2021 —
F-1 Registration statement (foreign issuer) Jan 19, 2021 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ADAG (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Jiangsu, China
SEC filer status
Accelerated filer, Emerging growth company
SEC CIK
1818838

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.